View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 20, 2020

Australian researchers trial hydroxychloroquine to prevent Covid-19

Researchers in Australia have launched a clinical trial to assess hydroxychloroquine for the prevention of Covid-19 in healthcare workers who are at high risk.

Researchers in Australia have launched a clinical trial to assess hydroxychloroquine for the prevention of Covid-19 in healthcare workers who are at high risk.

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

Named COVID SHIELD, the trial is enrolling frontline and allied healthcare professionals from hospitals across the country. It is being led by the Walter and Eliza Hall Institute of Medical Research in alliance with human data science firm IQVIA.

Lead investigators for the study are the Walter and Eliza Hall Institute’s Infectious Diseases and Immune Defence joint head Marc Pellegrini and Clinical Translation joint head Ian Wicks.

Pellegrini said: “COVID SHIELD is gold standard in its design as a multi-centre, randomised, double-blind study.

“The trial is focused on our frontline and allied healthcare workers who are at an increased risk of infection due to repeated exposure caring for sick patients. Our aim is to help these people stay safe, well, and able to continue in their vital roles.”

The trial will recruit 2,250 participants who will receive hydroxychloroquine or a placebo tablet over four months.

Wicks noted: “Rheumatologists are very comfortable with the drug’s safety profile. Like any medication hydroxychloroquine has certain side effects, but fortunately these are well known and quite uncommon.

“The medical specialists conducting COVID SHIELD are highly experienced in using hydroxychloroquine in the clinic. All participants will be screened based on rigorous selection criteria and closely monitored throughout the trial to ensure safety.”

Hydroxychloroquine is already being evaluated in multiple trials as a potential Covid-19 treatment. However, COVID SHIELD is said to be the first study to assess the drug as a prophylaxis or prevention against the disease.

The researchers intend to further investigate the antiviral activities demonstrated by hydroxychloroquine. The Australian Government is supporting the research.

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena